You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca has announced that it has entered into an agreement with Pfizer to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US. Under the terms of the agreement, Pfizer will make an upfront payment to Already a subscriber Login…
AstraZeneca plans to acquire the rights to Actavis' branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. When the transaction is finalized, AstraZeneca will own the develoAlready a subscriber Login You have read…
Xbrane Biopharma's efforts to divest the subsidiary Primm Pharma continues although negotiations with the previously expected acquirer NewFaDem for the time being has been paused. Primm Pharma is a fully owned subsidiary of Xbrane specialized in long-acting injectables and developer of SpherotideAlready a subscriber Login You have read all your…
Assay Depot, Inc., in conjunction with Astra Zeneca, recently developed and launched a preclinical research e-commerce platform called the AstraZeneca Innovation Marketplace (AIM). The program helps accelerate research and shorten the research cycle by automating legal and administrative processes. Already a subscriber Login You have read all your free articles,…
